Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia.

Pharmaceutics · 2024 · PMC11510096 · PMID 39458594

Europe PMC DOI

hedged sentence

0.0002

closest p · 0.0× alpha

0.0002

boldest claim

The sentences

highly significantp = 0.0002actually significant

Supplementing nirmatrelvir, in any concentration, results in a highly significant reduction in infectious titer (0.2 μM *** p = 0.0002, 0.1 μM *** p = 0.0003, 0.05 μM ** p = 0.019; Figure 2 c).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.